With AMI Buy, Angiotech Looks To Become Less Reliant On Partnerships
This article was originally published in The Gray Sheet
Executive Summary
Angiotech Pharmaceuticals' $785 mil. acquisition of American Medical Instruments Holdings will allow the firm to diversify its revenue stream and retain more control over its combination product business
You may also be interested in...
Taxus Free: Angiotech Carves Out New $625 Million Subsidiary
Combo product firm Angiotech Pharmaceuticals' creation of a new investor-supported subsidiary for its non-paclitaxel business could lead to an eventual spinoff of Angiotech Pharmaceutical Interventions, the firm announces July 7
Taxus Free: Angiotech Carves Out New $625 Million Subsidiary
Combo product firm Angiotech Pharmaceuticals' creation of a new investor-supported subsidiary for its non-paclitaxel business could lead to an eventual spinoff of Angiotech Pharmaceutical Interventions, the firm announces July 7
Angiotech Suspends Drug-Eluting Vascular Wrap Trials Over Safety Signals
Angiotech suspended enrollment April 21 in U.S. and European pivotal trials of its drug-eluting vascular graft mesh wrap due to safety concerns